Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is GHRP-2?
GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) is a second-generation synthetic hexapeptide GH secretagogue developed in the 1990s as a direct improvement over GHRP-6. It was engineered to retain the strong GH-releasing potency of GHRP-6 while reducing its problematic side effects — particularly the intense hunger stimulation caused by ghrelin receptor non-selectivity.
GHRP-2 succeeded in this goal partially: it produces a stronger GH pulse than GHRP-6 with reduced (but not eliminated) hunger and cortisol effects. It represents the intermediate step between GHRP-6's heavy side effect burden and ipamorelin's clean selectivity profile.
Mechanism of Action
GHRP-2 acts via the same fundamental pathway as all GHRPs:
- Binds GHS-R1a (ghrelin receptor) on pituitary somatotrophs
- Triggers intracellular calcium mobilization
- Releases stored GH in a pulsatile burst
- Acts synergistically with endogenous GHRH for amplified GH release
Compared to GHRP-6, GHRP-2 shows greater receptor binding affinity, explaining its higher GH potency. The structural modification that achieves partial reduction in hunger and cortisol effects is not fully characterized, but the difference in ghrelin response is meaningful — GHRP-2 causes less ghrelin elevation than GHRP-6, though more than ipamorelin (which causes essentially none).
Human Clinical Data
GHRP-2 has several human studies from the 1990s–2000s, making it better characterized than many newer peptides:
- Dose-dependent GH elevation demonstrated in healthy adults and GH-deficient patients
- IGF-1 elevation confirmed with repeated dosing
- ACTH and cortisol elevation documented — a key concern for sustained use
- Prolactin elevation documented at higher doses
- Used as a GH stimulation test in some endocrinology centers
GHRP-2's cortisol and prolactin elevation is the primary limitation for daily sustained longevity use. A transient post-injection cortisol rise is relatively benign in short cycles, but repeated daily stimulation over months creates an unfavorable anabolic-to-catabolic environment. This is why ipamorelin, which causes zero cortisol elevation, is preferred for the kind of daily 8–12 week cycles common in longevity protocols.
Practical Positioning Among GHRPs
GHRP-2 has a specific niche in the GHRP toolkit:
- Preferred over GHRP-6 when maximum GH potency is needed without GHRP-6's extreme hunger effect
- Less preferred than ipamorelin for daily longevity protocols due to cortisol/prolactin
- Short high-intensity cycles (4–6 weeks) where peak GH stimulus is the goal and cortisol is managed
- Combination with GHRH analogues: GHRP-2 + CJC-1295 or sermorelin produces synergistic GH amplification via independent pathways
Full GHRP Family Comparison
| Peptide | Potency | Hunger | Cortisol | Prolactin | Selectivity | Daily Use? | Best For |
|---|---|---|---|---|---|---|---|
| GHRP-6 | Strong | Strong (2–3×) | High | High | Low | No | Appetite stim, short cycles |
| GHRP-2 | Very strong | Moderate | Moderate | Moderate | Medium | Short cycles | Max GH with less hunger |
| Ipamorelin | Moderate | Minimal | None | None | High | Yes | Longevity, daily use |
| Hexarelin | Strongest | Moderate | Very high | High | Low | No | Cardiac, max potency |
Dosing Protocol
- Dose: 100–300 mcg subcutaneously per injection
- Receptor saturation note: GH response does not scale linearly above ~100–150 mcg per injection — higher doses increase cortisol more than GH
- Frequency: 1–3 times daily on empty stomach
- Pre-sleep injection: Most important — aligns with natural nocturnal GH pulse
- Cycle length: 4–8 weeks recommended due to cortisol concerns; cycling off prevents receptor desensitization
- GHRH combination: Add CJC-1295 no-DAC for synergistic effect via dual pathway
Monitoring
If using GHRP-2 in a clinical or supervised context, monitor:
- IGF-1: The proxy for GH activity — should move toward upper third of reference range
- Fasting glucose: GH promotes insulin resistance at elevated IGF-1 levels
- Morning cortisol: If using daily, check that baseline cortisol hasn't shifted significantly upward
- Prolactin: Elevated prolactin can reduce testosterone and libido in men
Frequently Asked Questions
GHRP-2 vs GHRP-6 — which is better?
GHRP-2 is generally considered superior to GHRP-6. It produces a stronger GH pulse with moderately reduced hunger and cortisol effects. For most users seeking maximum GH pulse in short cycles, GHRP-2 is the preferred first-generation alternative over GHRP-6.
GHRP-2 vs ipamorelin — which should I choose?
Ipamorelin is preferred for regular long-term use due to its selectivity — no cortisol or prolactin bleed. GHRP-2 produces a stronger GH pulse but with cortisol and prolactin elevation making it less suitable for daily sustained use. GHRP-2 is useful in short, high-intensity cycles where maximum GH stimulation is the primary goal and the cortisol is managed.
What is the correct dose of GHRP-2?
Standard GHRP-2 dosing is 100–300 mcg subcutaneously per injection on an empty stomach. GH response does not scale proportionally above 100–150 mcg due to receptor saturation — higher doses primarily increase cortisol more than GH. Injections 1–3 times daily; the pre-sleep injection is most important for aligning with the nocturnal GH pulse.
How much cortisol does GHRP-2 cause?
GHRP-2 causes moderate cortisol and prolactin elevation — less than GHRP-6 but more than ipamorelin. Single injections produce a transient cortisol rise peaking 15–30 minutes post-injection, normalizing within 1–2 hours. For daily long-term use, this chronic cortisol stimulation is the primary concern — which is why ipamorelin is generally preferred for sustained protocols.